Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHSA-GCSF for Chemotherapy-Induced Neutropenia in Breast Cancer
NCT03251768Phase 2Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rHSA-GCSF in neutropenia (2 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Duration of Severe Neutropenia. Started Oct 2017; status: completed.
02
Drugs
rHSA-GCSF
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03251768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251768.